Gary Krishnan

Evozyne CSO Gary Krishnan is an experienced scientific leader with a career spanning more than 26 years in the biopharma industry. Prior to joining Evozyne, Krishnan held multiple roles at Eli Lilly. Starting as a bench scientist, he spent over half his tenure in executive leadership positions, including Chief Scientific Officer for the Aging, Musculoskeletal, & Urology Research and Global Head of Translational Research for the Immunology business unit. Krishnan has a successful track record in drug development, advancing more than a dozen assets into clinical testing and serving as a key contributor to four of Lilly’s blockbuster drugs. He also led the discovery of one of the world’s first therapies for hospitalized COVID-19 patients. He holds a PhD in biochemistry and biophysics from Texas A&M University and completed his post-doctoral training at Baylor College of Medicine.